Abstract
Adjuvant chemotherapy reduces risk of relapse and cancer-related mortality in early stage breast cancer. Over the last decade, taxanes (paclitaxel and docetaxel) have been incorporated into various adjuvant trials and have demonstrated a significant benefit in the management of early stage breast cancer. Clinical trials using combinations of taxanes with targeted therapy have also shown considerable activity in breast cancer. This article reviews the pharmacology of docetaxel, a semi-synthetic taxane, and the clinical trials supporting its use in patients with node-positive breast cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 419-424 |
| Number of pages | 6 |
| Journal | Therapeutics and Clinical Risk Management |
| Volume | 4 |
| Issue number | 2 |
| State | Published - 2008 |
| Externally published | Yes |
Keywords
- Docetaxel
- Node-positive breast cancer
- Post-surgery treatment
- Taxanes
ASJC Scopus subject areas
- Safety Research
- Pharmacology, Toxicology and Pharmaceutics(all)
- Pharmacology (medical)
- Chemical Health and Safety